Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and
 daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus
 (HCV) infection when given for 12 or 24 weeks as measured by sustained virologic response
 with undetectable HCV RNA 12 weeks post treatment
Inclusion Criteria:

 -  Men and women, ages 18 to 70 years.

 -  Participants infected with hepatitis C virus (HCV) genotype 1, 2, or 3, with no
 previous exposure to an interferon formulation (ie, interferon-alpha, pegylated
 interferon-alpha) ribavirin, or other HCV-specific direct-acting antiviral (including
 daclatasvir and PSI-7977).

 -  Patients should have chronic hepatitis C genotype 1a, 1b, 2, or 3 as documented by:
 positive test results for anti-HCV antibody; HCV RNA; or a HCV genotype at least 6
 months prior to screening, and HCV RNA and anti-HCV antibody at the time of screening.

 Exclusion Criteria:

 -  Evidence of a medical condition associate with chronic liver disease other than HCV.

 -  History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
 with diuretics or paracentesis.

 -  History of hemophilia.

 -  History of torsade de pointes.

 -  Current or known history of cancer (except in situ carcinoma of the cervix or
 adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
 to enrollment.

 -  History of gastrointestinal disease or surgical procedure (except cholecystectomy).

 -  History of clinically significant cardiac disease.

 -  Blood transfusion within 4 weeks prior to study drug administration.

 -  Poor venous access.

 -  Any other medical, psychiatric, and/or social reason which, in the opinion of the
 Investigator, would make the candidate inappropriate for participation in this study.